John Libbey Eurotext

European Journal of Dermatology


Rapid regression of metastatic brain tumours in a melanoma patient after dabrafenib/trametinib therapy Volume 27, numéro 5, September-October 2017


  • Figure 1
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Malignant melanoma is the malignancy with the highest rate of metastatic dissemination to the central nervous system (CNS) [1]. A combination of dabrafenib (a V600-mutated BRAF inhibitor) and trametinib (a MEK inhibitor [serving as an escape mechanism from BRAF inhibition]) (DT) therapy is expected to have an effect on brain metastasis, but the efficacy of DT therapy on brain metastasis is still under investigation since patients with brain metastases were excluded from a recent trial [2]. To date, [...]